

JC969
10/12/00
PTO

08-27-01

CD inside
BOX seg A

PTO/PR/2005 (2)

Approved for use through 09/30/2000. OMB No. 0651-0051.

Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

08/24/01
08/24/01

Please type a plus sign (+) inside this box → **[+]**

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 C.F.R. §1.53(b))

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents

- *Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original, and a duplicate for fee processing)
- Specification [Total Pages **78**]]
- Descriptive title of the Invention
- Cross References to Related Applications
- Statement Regarding Fed sponsored R&D
- Reference in Microfiche Appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings (*if filed*)
- Detailed Description
- Claim(s)
- Abstract of the Disclosure
- Drawing(s) (35 U.S.C. 11.3) [Total sheets **10**]]
- Oath or Declaration [Total pages]]

 - a. Newly executed (original or copy)
 - b. Copy from a prior application (37 CFR §1.63(d))
(for continuation/divisional with Box 17 completed)
[Note Box 5 below]
 - i. DELETION OF INVENTOR(S)
Signed statement attached deleting Inventor(s) named in the prior application, see 37 C.F.R. §§1.63(d)(2) and 1.33(b).

- Incorporation By Reference (*useable if Box 4b is checked*)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

ADDRESS TO:
Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

- Microfiche Computer Program (Appendix)
- Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
 - a. Computer Readable Copy
 - b. Paper Copy (identical to computer copy)
 - c. Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

- Assignment Papers (cover sheet & document(s))
- 37 C.F.R. § 37.3(b) Statement Power of Attorney
- English Translation Document (*if applicable*)
- Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations
- Preliminary Amendment
- Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
- *Small Entity Statement filed in prior application, Statement(s) (*PTO/SB/09-12*) Status still proper and desired
- Certified Copy of Priority Document(s)
(if foreign priority is claimed)
- Other: Priority Claimed from United States Provisional Application No. 60/227,924, filed August 25, 2000.

*NOTE FOR ITEMS 1 & 14: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

 Continuation Divisional Continuation-in-part (CIP) of prior application No.

Prior application information: Examiner

Group/Art Unit:

18. CORRESPONDENCE ADDRESS

<input type="checkbox"/> Customer Number or Bar Code Label		(Insert Customer No. or Attach bar code label here)		<input checked="" type="checkbox"/> Correspondence address below
Name	Paul H. Ginsburg			
Address	Pfizer Inc			
Address	235 East 42nd Street, 20th Floor			
City	New York	State	New York	Zip Code
Country	United States Of America	Telephone	(212)573-2369	Fax
NAME (Print/type):		Lorraine B. Ling	Registration No. (Attorney/Agent)	35,251
Signature		<i>Lorraine B. Ling</i>	Date	August 24, 2001

EXPRESS MAIL NO. EL639818049US

UTILITY TRANSMITTAL PTO SB 05, 3/99, (1/1)

FEE TRANSMITTAL

Patent fees are subject to annual revision on October 1.
These are the fees effective October 1, 1997.

Small Entity payments must be supported by a small entity statement,
otherwise large entity fees must be paid. See Forms PTO/SB/09-12.

See 37 C.F.R. §§ 1.27 and 1.28.

Total Amount of Payment (\$2,278.00)

Complete If Known

Application Number	Not Yet Assigned
Filing Date	Herewith
First Named Inventor	Tong, et al.
Examiner Name	Not Yet Assigned
Group/Art Unit	Not Yet Assigned
Attorney Docket No.	PC10790A

METHOD OF PAYMENT (check one)

- The Commissioner is hereby authorized to charge indicated fees and credit any over payments to:

Deposit Account Number 16-1445

Deposit Account Name

Charge Any Additional Fee Required Under 37 C.F.R. § 1.18 at the Mailing of the Notice of Allowance.

Charge the Issue Fee Set in 37 C.F.R. § 1.18 at the Mailing of the Notice of Allowance.

2. Payment Enclosed:

Check Money Order Other

FEE CALCULATION (continued)

3. ADDITIONAL FEES		Fee Description				Fee Paid
Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Code	Fee (\$)	
		105	130	205	65	Surcharge - late fee or oath
		127	50	227	25	Surcharge-late provisional filing fee or cover sheet
		139	130	139	130	Non-English specification
		147	2,520	147	2,520	For filing a request for reexamination
		112	920*	112	920*	Requesting publication of SIR prior to Examiner action
		113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action
		115	110	215	55	Extension for reply within first month
		116	390	216	195	Extension for reply within second month
		117	890	217	445	Extension for reply within third month
		118	1,390	218	695	Extension for reply within fourth month
		128	1,890	228	945	Extension for reply within fifth month
		119	310	219	155	Notice of Appeal
		120	310	220	155	Filing a brief in support of an appeal
		121	270	221	135	Request for oral hearing
		138	1,510	138	1,510	Petition to institute a public use proceeding
		140	110	240	55	Petition to revive - unavoidable
		141	1,240	241	620	Petition to revive - unintentional
		142	1,240	242	620	Utility issue fee (or reissue)
		143	440	243	220	Design issue fee
		144	600	244	300	Plant issue fee
		122	130	122	130	Petitions to the Commissioner
		123	50	123	50	Petitions related to provisional applications
		126	240	126	240	Submission of Information Disclosure Statement
		581	40	581	40	Recording each patent assignment per property (times number of properties)
		146	710	246	355	Filing a submission after final rejection (37 CFR 1.12(e)(1))
		149	710	249	355	For each additional invention to be examined (37 CFR 1.12(g)(6))
		Other Fee (specify)				
		Other Fee (specify)				
		*Reduced by Basic Filing Fee Paid				
		SUBTOTAL (3) (\$)				

** or number previously paid, if greater; For Reissues, see below

Large Entity	Small Entity			
Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description
103	16	203	9	Claims in excess of 20
102	80	202	40	Independent claims in excess of 3
104	270	204	135	Multiple dependent claim, if not paid
109	80	209	40	**Reissue independent claims over original patent
110	18	210	9	**Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$ 2,278.00)

SUBTOTAL (3) (\$)

SUBMITTED BY

Type or Printed Name	Lorraine B. Ling	Complete (if Applicable)
Signature	<i>Lorraine B. Ling</i>	Reg. Number 35,251 Deposit Account User ID

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

TONG, ET AL.

APPLICATION NO.: **Not Yet Assigned**

Examiner: **Not Yet Assigned**

FILING DATE: **Herewith**

Group Art Unit: **Not Yet
Assigned**

**TITLE: METHODS AND COMPOSITIONS
FOR DIAGNOSING AND TREATING
DISORDERS INVOLVING
ANGIOGENESIS**

Commissioner for Patents
Washington, D.C. 20231

Sir:

STATEMENT UNDER 37 CFR 1.821

I hereby state that the information recorded in computer readable form is the same as the written sequence listing.

Respectfully submitted,

Date: August 24, 2001

Lorraine B. Ling
Lorraine B. Ling
Attorney for Applicant(s)
Reg. No. 35,251

Pfizer Inc
Patent Department, 5th Fl.
150 East 42nd Street
New York, NY 10017-5612
(212) 573-2030

EXPRESS MAIL NO.: EL639818049US